FDA Approves First Freeze-Dried Plasma Product for Emergency Transfusion

First U.S. Approval for Lyophilized Plasma Technology

The United States Food and Drug Administration (FDA) has granted biologics licensure for Ezplaz Freeze Dried Plasma (FDP), marking the first time a freeze-dried plasma product has received regulatory licensure for clinical use in the United States ^[3][7]. The regulatory approval, granted to Vascular Solutions, LLC, a subsidiary of Teleflex, introduces a lyophilized blood component engineered to address longstanding logistical challenges in prehospital, military, and austere emergency care settings ^[3][5][7]. Ezplaz is indicated specifically for transfusion in adult patients when plasma is required and conventional plasma products are unavailable ^[2][3].

Under standard clinical conditions, conventional plasma must remain frozen and requires dedicated electrical refrigeration and controlled thawing equipment before it can be administered safely to patients ^[3][5]. These logistical constraints historically limited plasma availability in out-of-hospital emergencies, remote rural environments, disaster zones, and active combat areas ^[3][5]. Because hemorrhage represents a major cause of preventable trauma mortality, delivering essential clotting proteins directly to bleeding patients without delay is critical for stabilizing coagulopathy and preventing circulatory collapse ^[3][5].

Form Factor, Packaging, and Rapid Reconstitution

Ezplaz is prepared by freeze-drying a single unit of fresh frozen plasma sourced from FDA-licensed blood establishments ^[3][7]. The finished product is provided as an off-white to dark amber lyophilized powder sealed inside a single-use flexible plastic bag within an outer foil pouch ^[2][3][7]. Unlike foreign emergency-use dried plasma formulations that utilize glass containers, the flexible plastic packaging of Ezplaz is designed to prevent container breakage during transport and rugged field handling ^[3][5][7].

The dry formulation remains stable at ambient room temperature, maintaining storage integrity for up to 12 months between 2 and 25 degrees Celsius (36 to 77 degrees Fahrenheit) while showing resilience against temperature fluctuations ^[3][5]. When emergency transfusion is required, the dry powder is reconstituted using the sterile water provided in the unit kit ^[2][3][5]. Reconstitution is completed in approximately 2.5 minutes, yielding a near-uniform, cloudy liquid equivalent to 270 mL of standard human plasma that is ready for immediate administration ^[2][5].

Each commercial kit is distributed as a self-contained, complete package designed for rapid deployment without supplemental hospital equipment ^[2][3][7]. The kit includes one unit of freeze-dried plasma in a sealed foil pouch, one 250 mL bag of USP-grade Sterile Water for Injection (SWFI), one sterile fluid transfer set, and one sterile blood transfusion set ^[2][3]. Clinicians can administer the reconstituted fluid via intravenous (IV) or intraosseous (IO) access, provided the entire infusion is completed within four hours of reconstitution under recommended storage conditions ^[2].

Blood Typing Strategy and Safety Indications

To minimize immunological risks in time-critical trauma cases where recipient blood typing cannot be determined beforehand, Ezplaz is manufactured in two specific blood groups: Group AB plasma and Group A plasma selected for low-titer anti-B antibodies ^[3][5][7]. Selecting these specific profiles mitigates the likelihood of acute hemolytic transfusion reactions caused by ABO incompatibility when emergency personnel administer plasma empirically before cross-matching ^[3][5][7].

The FDA approved Ezplaz for adult patients suffering from severe bleeding, patients requiring massive transfusions with clinically significant coagulation deficiencies, and patients on warfarin therapy experiencing acute hemorrhage or requiring urgent reversal before invasive procedures when alternative vitamin K treatments cannot take effect in time ^[2][3][5]. Regulatory documentation notes that the product is strictly indicated for situations where conventional plasma products are unavailable and emphasizes that it is not intended for routine volume expansion ^[2][3].

Licensure followed regulatory programs established under Public Law 115-92, passed in December 2017 to facilitate collaboration between the Department of Defense (now DoW) and the FDA to accelerate countermeasures for life-threatening battlefield conditions ^[3][7]. In early safety trials evaluated by the FDA involving 24 healthy adult participants, investigators reported no deaths, serious adverse events, or treatment-related adverse reactions ^[5]. However, the safety warnings for Ezplaz remain aligned with general plasma transfusions, carrying risks of allergic responses, transfusion-related acute lung injury (TRALI), volume overload, and potential infection transmission ^[2][5][7]. Additionally, a post-approval surveillance study will monitor incompletely characterized risks, including potential thromboembolic events following administration ^[5].

Sources

1. HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------CONTRAINDICATIONS-------------------- These highlights do not include all the information needed Do not use EZPLAZ™ FDP: to teleflex.com
2. FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S. content.govdelivery.com
3. The FDA Just Approved The First US Freeze-Dried Plasma, Ready in Minutes : ScienceAlert www.sciencealert.com
4. FDA Licenses First-Ever Freeze-Dried Plasma Product in the www.globenewswire.com